# European oncology congress: therapeutic advances against cancer > Late October 2026, several announcements report therapeutic advances against cancer: an immunotherapy extending survival in small-cell lung cancer, a new family of drugs for gynecological cancers, and a personalized melanoma vaccine showing promising results. On October 27, a study indicates that second-generation hormone therapy as a complement significantly prolongs survival in metastatic prostate cancer. On October 29, Professor Jean-Jacques Kiladjian highlights the gap between announcements of promising treatments and their effective access for patients, after the European oncology congress. Late October, a European oncology summit notably presents the melanoma vaccine and new promising treatments. Early November, studies mention enhanced immunotherapies and antibody-drug conjugates against resistant tumors, ultrasound for prostate cancer, funding for the French ATLAS team on autoantibodies, and therapeutic vaccines as a growing avenue. **In brief**: Ongoing story bringing together 10 events nationwide, followed from 26 October 2026 to 8 November 2026. 30 articles from 13 sources (health); last updated on 8 November 2026 at 10:00. - Status: ongoing - Category: Health - Place: Nationwide - First detected: 26 October 2026 at 11:15 - Updated: 8 November 2026 at 10:00 - Web page: https://acturadar.com/en/stories/172-european-oncology-congress-therapeutic-advances-against-cancer ## Reported figures - 25 000 euros ## Timeline (10 events) ### 26 October 2026 — [New immunotherapy extends survival in lung cancer](https://acturadar.com/en/events/717-new-immunotherapy-extends-survival-in-lung-cancer.md) Two new treatments for small cell lung cancer improve patients' survival, with a survival gain described as "never seen". 2 sources, 4 articles · Nationwide ### 26 October 2026 — [A new family of drugs against gynecological cancers](https://acturadar.com/en/events/842-a-new-family-of-drugs-against-gynecological-cancers.md) A new family of treatments raises hope in the management of gynecological cancers. 1 sources, 1 articles · Nationwide ### 26 October 2026 — [A promising tailor-made vaccine against melanoma recurrences](https://acturadar.com/en/events/1370-a-promising-tailor-made-vaccine-against-melanoma-recurrences.md) A personalized vaccine against melanoma shows promising results, with 82% of treated patients not experiencing a recurrence. 9 sources, 11 articles · Nationwide ### 27 October 2026 — [Metastatic prostate cancer: hormone therapy extends survival by two years](https://acturadar.com/en/events/1433-metastatic-prostate-cancer-hormone-therapy-extends-survival-by-two-years.md) A study shows that a second-generation hormone therapy administered as a supplement significantly increases survival in patients with metastatic prostate cancer. 3 sources, 4 articles · Nationwide ### 29 October 2026 — [Cancer research: between treatment promises and delays in access to care](https://acturadar.com/en/events/3625-cancer-research-between-treatment-promises-and-delays-in-access-to-care.md) Following the European oncology congress, Professor Jean-Jacques Kiladjian explains the gap between announcements of promising treatments and their effective access for patients. 1 sources, 1 articles · Nationwide ### 30 October 2026 — [Therapeutic advances against cancer presented at European oncology summit](https://acturadar.com/en/events/4639-therapeutic-advances-against-cancer-presented-at-european-oncology-summit.md) A melanoma vaccine and promising new treatments are among the medical advances presented at a European oncology summit. 1 sources, 1 articles · Nationwide ### 2 November 2026 — [Cancer : des pistes d'immunothérapie renforcée contre les tumeurs résistantes](https://acturadar.com/en/events/7689-cancer-des-pistes-d-immunotherapie-renforcee-contre-les-tumeurs-resistantes.md) Des travaux présentés notamment au congrès AFSOS évoquent des immunothérapies plus puissantes et des anticorps conjugués contre les tumeurs résistantes. Des essais d'injections d'immunothérapie sont menés à Villejuif. 1 sources, 1 articles · Nationwide ### 2 November 2026 — [Cancer de la prostate : des ultrasons pour détruire la tumeur sans opérer](https://acturadar.com/en/events/6758-cancer-de-la-prostate-des-ultrasons-pour-detruire-la-tumeur-sans-operer.md) Un article revient sur le traitement du cancer de la prostate par ultrasons, une alternative à la chirurgie. Près de 60 000 hommes sont diagnostiqués chaque année en France. 2 sources, 2 articles · Nationwide ### 4 November 2026 — [Cancer : l'équipe française ATLAS décroche un financement pour étudier les auto-anticorps](https://acturadar.com/en/events/8909-cancer-l-equipe-francaise-atlas-decroche-un-financement-pour-etudier-les-auto.md) L'équipe française ATLAS obtient un financement international de grande envergure pour percer le rôle des auto-anticorps dans la résistance naturelle au cancer. 4 sources, 4 articles · Nationwide ### 8 November 2026 — [Le vaccin, nouvel outil de lutte contre le cancer](https://acturadar.com/en/events/13559-le-vaccin-nouvel-outil-de-lutte-contre-le-cancer.md) Les vaccins thérapeutiques apparaissent comme une piste croissante dans la lutte contre le cancer, en complément des autres approches de recherche présentées récemment. 1 sources, 1 articles · Nationwide --- Cite as: Acturadar, “European oncology congress: therapeutic advances against cancer”, https://acturadar.com/en/stories/172-european-oncology-congress-therapeutic-advances-against-cancer Methodology: https://acturadar.com/en/methodology